Last reviewed · How we verify
DW6012(Dasidiem tab. 10/100mg)
DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation.
DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
At a glance
| Generic name | DW6012(Dasidiem tab. 10/100mg) |
|---|---|
| Also known as | Piotazone tab., Sitdiem tab. 100mg |
| Sponsor | Dong Wha Pharmaceutical Co. Ltd. |
| Drug class | Tyrosine kinase inhibitor combination |
| Target | BCR-ABL, SRC family kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Dasatinib is a multi-targeted tyrosine kinase inhibitor that blocks BCR-ABL and other kinases implicated in hematologic malignancies. The 10/100 mg formulation suggests a combination product, likely pairing dasatinib with a complementary agent to enhance efficacy or tolerability in chronic myeloid leukemia or acute lymphoblastic leukemia.
Approved indications
- Chronic myeloid leukemia (CML)
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Common side effects
- Pleural effusion
- Diarrhea
- Rash
- Cytopenias
- Fluid retention
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DW6012(Dasidiem tab. 10/100mg) CI brief — competitive landscape report
- DW6012(Dasidiem tab. 10/100mg) updates RSS · CI watch RSS
- Dong Wha Pharmaceutical Co. Ltd. portfolio CI